407 related articles for article (PubMed ID: 31596514)
41. Identification of new [1,2,4]triazolo[4,3-a]quinoxalines as potent VEGFR-2 tyrosine kinase inhibitors: Design, synthesis, anticancer evaluation, and in silico studies.
Alsaif NA; Taghour MS; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari A; Albassam H; Dahab MA; Mahdy HA
Bioorg Med Chem; 2021 Sep; 46():116384. PubMed ID: 34479065
[TBL] [Abstract][Full Text] [Related]
42. Design, synthesis and molecular docking of new [1,2,4] triazolo[4,3-a]quinoxaline derivatives as anticancer agents targeting VEGFR-2 kinase.
Alsaif NA; Elwan A; Alanazi MM; Obaidullah AJ; Alanazi WA; Alasmari AF; Albassam H; Mahdy HA; Taghour MS
Mol Divers; 2022 Aug; 26(4):1915-1932. PubMed ID: 34460053
[TBL] [Abstract][Full Text] [Related]
43. Iodoquinazoline-derived VEGFR-2 and EGFR
Mohamed AA; El-Hddad SSA; Aljohani AKB; Khedr F; Alatawi OM; Keshek DE; Ahmed S; Alsulaimany M; Almadani SA; El-Adl K; Hanafy NS
Bioorg Chem; 2024 Feb; 143():107062. PubMed ID: 38150938
[TBL] [Abstract][Full Text] [Related]
44. Design, synthesis, molecular docking and in silico ADMET profile of pyrano[2,3-d]pyrimidine derivatives as antimicrobial and anticancer agents.
Abd El-Sattar NEA; El-Adl K; El-Hashash MA; Salama SA; Elhady MM
Bioorg Chem; 2021 Oct; 115():105186. PubMed ID: 34314914
[TBL] [Abstract][Full Text] [Related]
45. EGFR/VEGFR-2 dual inhibitor and apoptotic inducer: Design, synthesis, anticancer activity and docking study of new 2-thioxoimidazolidin-4one derivatives.
Mourad AAE; Farouk NA; El-Sayed EH; Mahdy ARE
Life Sci; 2021 Jul; 277():119531. PubMed ID: 33887348
[TBL] [Abstract][Full Text] [Related]
46. Design, molecular docking, in vitro, and in vivo studies of new quinazolin-4(3H)-ones as VEGFR-2 inhibitors with potential activity against hepatocellular carcinoma.
Eissa IH; Ibrahim MK; Metwaly AM; Belal A; Mehany ABM; Abdelhady AA; Elhendawy MA; Radwan MM; ElSohly MA; Mahdy HA
Bioorg Chem; 2021 Feb; 107():104532. PubMed ID: 33334586
[TBL] [Abstract][Full Text] [Related]
47. Novel potent substituted 4-amino-2-thiopyrimidines as dual VEGFR-2 and BRAF kinase inhibitors.
Abdel-Mohsen HT; Omar MA; El Kerdawy AM; Mahmoud AEE; Ali MM; El Diwani HI
Eur J Med Chem; 2019 Oct; 179():707-722. PubMed ID: 31284081
[TBL] [Abstract][Full Text] [Related]
48. Discovery of novel indolyl-1,2,4-triazole hybrids as potent vascular endothelial growth factor receptor-2 (VEGFR-2) inhibitors with potential anti-renal cancer activity.
Al-Hussain SA; Farghaly TA; Zaki MEA; Abdulwahab HG; Al-Qurashi NT; Muhammad ZA
Bioorg Chem; 2020 Dec; 105():104330. PubMed ID: 33038552
[TBL] [Abstract][Full Text] [Related]
49. Benzoxazole derivatives as new VEGFR-2 inhibitors and apoptosis inducers: design, synthesis,
Taghour MS; Mahdy HA; Gomaa MH; Aglan A; Eldeib MG; Elwan A; Dahab MA; Elkaeed EB; Alsfouk AA; Khalifa MM; Eissa IH; Elkady H
J Enzyme Inhib Med Chem; 2022 Dec; 37(1):2063-2077. PubMed ID: 35875937
[TBL] [Abstract][Full Text] [Related]
50. Discovery of novel VEGFR-2 inhibitors embedding 6,7-dimethoxyquinazoline and diarylamide fragments.
Wang R; Liu H; You YY; Wang XY; Lv BB; Cao LQ; Xue JY; Xu YG; Shi L
Bioorg Med Chem Lett; 2021 Mar; 36():127788. PubMed ID: 33460739
[TBL] [Abstract][Full Text] [Related]
51. Design, synthesis and biological evaluation of some novel benzothiazole/benzoxazole and/or benzimidazole derivatives incorporating a pyrazole scaffold as antiproliferative agents.
Abdelgawad MA; Bakr RB; Omar HA
Bioorg Chem; 2017 Oct; 74():82-90. PubMed ID: 28772160
[TBL] [Abstract][Full Text] [Related]
52. Design, synthesis and docking study of novel picolinamide derivatives as anticancer agents and VEGFR-2 inhibitors.
Zeidan MA; Mostafa AS; Gomaa RM; Abou-Zeid LA; El-Mesery M; El-Sayed MA; Selim KB
Eur J Med Chem; 2019 Apr; 168():315-329. PubMed ID: 30826508
[TBL] [Abstract][Full Text] [Related]
53. Design, synthesis and molecular modeling of new quinazolin-4(3H)-one based VEGFR-2 kinase inhibitors for potential anticancer evaluation.
Abdallah AE; Eissa SI; Al Ward MMS; Mabrouk RR; Mehany ABM; El-Zahabi MA
Bioorg Chem; 2021 Apr; 109():104695. PubMed ID: 33647743
[TBL] [Abstract][Full Text] [Related]
54. Design, synthesis, in vitro and in silico evaluation of novel substituted 1,2,4-triazole analogues as dual human VEGFR-2 and TB-InhA inhibitors.
Zawal AG; Abdel-Aziz MM; Elbatreek MH; El-Shanawani AA; Abdel-Aziz LM; Elbaramawi SS
Bioorg Chem; 2023 Dec; 141():106883. PubMed ID: 37774433
[TBL] [Abstract][Full Text] [Related]
55. [1,2,4]Triazolo[4,3-c]quinazoline and bis([1,2,4]triazolo)[4,3-a:4',3'-c]quinazoline derived DNA intercalators: Design, synthesis, in silico ADMET profile, molecular docking and anti-proliferative evaluation studies.
El-Adl K; Ibrahim MK; Alesawy MSI; Eissa IH
Bioorg Med Chem; 2021 Jan; 30():115958. PubMed ID: 33360576
[TBL] [Abstract][Full Text] [Related]
56. New benzothiazole hybrids as potential VEGFR-2 inhibitors: design, synthesis, anticancer evaluation, and
Al-Sanea MM; Hamdi A; Mohamed AAB; El-Shafey HW; Moustafa M; Elgazar AA; Eldehna WM; Ur Rahman H; Parambi DGT; Elbargisy RM; Selim S; Bukhari SNA; Magdy Hendawy O; Tawfik SS
J Enzyme Inhib Med Chem; 2023 Dec; 38(1):2166036. PubMed ID: 36691927
[TBL] [Abstract][Full Text] [Related]
57. Novel piperazine-chalcone hybrids and related pyrazoline analogues targeting VEGFR-2 kinase; design, synthesis, molecular docking studies, and anticancer evaluation.
Ahmed MF; Santali EY; El-Haggar R
J Enzyme Inhib Med Chem; 2021 Dec; 36(1):307-318. PubMed ID: 33349069
[TBL] [Abstract][Full Text] [Related]
58. Indoline ureas as potential anti-hepatocellular carcinoma agents targeting VEGFR-2: Synthesis, in vitro biological evaluation and molecular docking.
Eldehna WM; Fares M; Ibrahim HS; Aly MH; Zada S; Ali MM; Abou-Seri SM; Abdel-Aziz HA; Abou El Ella DA
Eur J Med Chem; 2015 Jul; 100():89-97. PubMed ID: 26071861
[TBL] [Abstract][Full Text] [Related]
59. Design, synthesis and biological evaluation of pyrimidine-based derivatives as VEGFR-2 tyrosine kinase inhibitors.
Sun W; Hu S; Fang S; Yan H
Bioorg Chem; 2018 Aug; 78():393-405. PubMed ID: 29677483
[TBL] [Abstract][Full Text] [Related]
60. Synthesis and biological evaluation of 2-styrylquinolines as antitumour agents and EGFR kinase inhibitors: molecular docking study.
El-Sayed MA; El-Husseiny WM; Abdel-Aziz NI; El-Azab AS; Abuelizz HA; Abdel-Aziz AA
J Enzyme Inhib Med Chem; 2018 Dec; 33(1):199-209. PubMed ID: 29251017
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
